4D Molecular Therapeutics up 85% on good news for patients with macular degeneration

Aescap portfolio company 4DMT saw its share price increase by 85% yesterday after it announced positive results from its clinical trial for a gene therapy treatment of a form of macular degeneration (Wet AMD).

Macular degeneration

Wet AMD is a highly prevalent disease with more than 2 million people affected and an estimated over 400.000 new patients per year in the EU and US together.

The treatment of 4DMT consists of only one injection versus the current treatment that needs frequent (up to monthly) and life-long injections in the eye.

4D Molecular Therapeutics

4DMT is a clinical-stage genetic medicines company focused on medicines to treat large groups of patients suffering from diseases in ophthalmology, pulmonology, and cardiology. Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates.

4DMT is a portfolio company of the Aescap Genetics fund. Before the share price increase the company was 4,7% of the fund.